Key facts
- This page summarizes Nirav S. Jhaveri's Form 4 filing for Opus Genetics, Inc. (IRD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Mar 2025, 20:52.
Nirav S. Jhaveri - 13 Mar 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- IRD
- Reported as of
- 13 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Mar 2025, 20:52:04 UTC
- Prior SEC filing
- 18 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy Rabourn, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nirav S. Jhaveri filed Form 4 for Opus Genetics, Inc. (IRD) on 17 Mar 2025.
Change
- Previous filing in this sequence was filed on 18 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRD
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +52,500
- Change %
- +37%
- Price
- $0.000000
- Shares after
- 194,293
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRD
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +52,500
- Change %
- Price
- $0.000000
- Shares after
- 52,500
- Date
- 13 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,500
- Exercise price
- $0.9300
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service.
Footnote F2
The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service.